| Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2015: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2014: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Outline of Final Research Achievements |
CREBH is a transcription factor, which is expressed in liver and intestine. Liver-specific CREBH Tg mice were generated, which suppressed diet-induced obesity and diabetes. CREBH and PPARα synergistically regulated hepatic FGF21 expression. CREBH KO mice showed atherosclerosis and non-alcoholic fatty liver disease. Conversely, CREBH Tg suppressed atherosclerosis. Using CRISPR/Cas9 system, we firstly generated liver-specific CREBH knockout mice, which exhibited non-alcoholic fatty liver disease, suggesting that liver CREBH, but not intestine CREBH, is important for the pathology of non-alcoholic fatty liver disease
|
